ArticleTrials2025
The Antibiotic effect of Silver CAPD Catheter on Peritoneal Dialysis-related infections (ASCA-PD) study: a multicenter randomized open-label trial protocol.
Article in Trials, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
31 authors.
Funding
Abstract
backgroundPeritoneal dialysis (PD) offers greater flexibility than hemodialysis, especially in patients with limited mobility or demanding schedules; however, PD-related infection is a major complication and a cause of withdrawal from peritoneal dialysis. The Antibiotic effect of Silver continuous ambulatory peritoneal dialysis (CAPD) Catheter on Peritoneal Dialysis-related infections (ASCA-PD) study will evaluate the effectiveness of a novel silver CAPD catheter, incorporating silver-based antimicrobial technology, for preventing these infections and improving PD adherence. METHODS/
designThis randomized, open-label, parallel-group, multicenter trial will evaluate the efficacy and safety of a silver CAPD catheter compared with those of a conventional catheter at 14 Japanese facilities. A total of 250 adult patients with newly initiated PD will be enrolled and randomized 1:1 to receive either catheter type. The key exclusion criteria are prior PD, emergency PD initiation, non-abdominal exit-site placement, metal allergy, life expectancy <1 year, severe liver disease, certain dermatologic conditions, and immunosuppression. After providing informed consent, patients will undergo nasal swab screening for methicillin-resistant Staphylococcus aureus. Randomization will be stratified by facility and diabetes status. The primary outcome is the composite endpoint of all exit-site and tunnel infections within 12 months of PD initiation. Secondary outcomes include individual infection events, catheter removal, peritonitis, catheter patency, allergic reactions, technique failure (transition to hemodialysis for ≥30 days or death), and transition to hybrid dialysis. A Poisson regression model will be used to analyze the primary outcome, adjusting for observation time, treatment group, and stratification factors. Time-to-event secondary outcomes will be analyzed by competing risk regression. Subgroup analyses will be carried out to explore the impacts of age, sex, diabetes, insertion method, and body mass index. DISCUSSION: Unlike previous designs, our silver CAPD catheter incorporates AgNPs into silicone, enabling sustained antimicrobial effects both externally and internally, potentially overcoming limitations seen in prior human studies. This study will demonstrate the efficacy of silver CAPD catheters for preventing PD-related infections, especially during the initiation phase of PD, with the aim of providing a new therapeutic option.
trial registrationJapan Registry of Clinical Trials, jRCTs052250003. Registered on April 4, 2025.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.